Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.435 +0.035 (+2.50%)

Delayed Quote Updated: 1:24 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

< Previous 1 2 3 4 5 Next >

ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

April 02, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ACTINIUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

March 31, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

March 31, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Actinium Pharmaceuticals, Inc. (ATNM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 31, 2025

From Law Offices of Howard G. Smith

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

March 28, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

March 28, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 27, 2025

From The Schall Law Firm

Via Business Wire

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)

March 27, 2025

From Scott+Scott Attorneys at Law LLP

Via Business Wire

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

March 27, 2025

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 26, 2025

Via Benzinga

Top movers in Wednesday's pre-market session ↗

March 26, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 25, 2025

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week ↗

March 23, 2025

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Via Stocktwits

Which stocks are gapping on Thursday? ↗

March 20, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A’s Backbone Therapy Strategy

March 20, 2025

New York, NY – March 20, 2025 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has...

Via FinancialNewsMedia

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 25, 2024

Via Benzinga

Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

August 18, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

August 09, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

August 07, 2024

From The Schall Law Firm

Via Business Wire

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024 ↗

August 06, 2024

ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

August 06, 2024

Via Benzinga

S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge ↗

August 05, 2024

Via Benzinga

Topics Stocks

Dow Tumbles 950 Points; ISM Services PMI Surges In July ↗

August 05, 2024

Via Benzinga

Topics Stocks

Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment ↗

August 05, 2024

FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequate support despite achieving a statistically significant primary endpoint. Actinium...

Via Benzinga

Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views ↗

August 05, 2024

Via Benzinga

3 Under-$10 Biotech Stocks That Could Make You Rich ↗

July 11, 2024

Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.

Via InvestorPlace

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns ↗

July 02, 2024

These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline.

Via InvestorPlace

Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

June 18, 2024

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and...

Via Newsfile

Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

June 18, 2024

Via AB Newswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.